Aug 29, 2019 9:24am EDT OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency
Aug 07, 2019 4:05pm EDT OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results
Aug 01, 2019 8:00am EDT OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019
Jul 01, 2019 9:29am EDT OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers
May 07, 2019 4:20pm EDT OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results
Apr 12, 2019 8:00am EDT OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial
Mar 21, 2019 8:00am EDT OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial